SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of SOPHiA GENETICS in a research report issued to clients and investors on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.77) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.02) EPS.
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million.
View Our Latest Research Report on SOPH
SOPHiA GENETICS Stock Performance
NASDAQ:SOPH opened at $6.69 on Friday. The firm has a 50-day moving average of $5.57 and a two-hundred day moving average of $5.13. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 1.90. The stock has a market cap of $561.22 million, a P/E ratio of -5.82 and a beta of 0.96. SOPHiA GENETICS has a 1-year low of $2.96 and a 1-year high of $7.21.
Insider Activity at SOPHiA GENETICS
In related news, insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $5.66, for a total value of $28,300.00. Following the completion of the sale, the insider directly owned 223,387 shares of the company’s stock, valued at $1,264,370.42. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total value of $69,200.00. Following the sale, the insider owned 600,887 shares in the company, valued at $4,158,138.04. The trade was a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 256,092 shares of company stock worth $1,492,420 over the last quarter. Company insiders own 4.88% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the last quarter. Principal Financial Group Inc. boosted its position in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS during the 1st quarter worth $50,000. Finally, Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.
Trending Headlines about SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. Management continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
- Positive Sentiment: The company entered a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The partnership could expand SOPH’s commercial reach and provide longer-term growth opportunities. SOPHiA GENETICS AstraZeneca partnership article
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $12 to $14. BTIG Research also maintained a Buy rating and lifted its target from $8 to $9, signaling improved confidence in the company’s growth prospects.
- Positive Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million, surpassing the $21.72 million consensus estimate. The adjusted EBITDA loss also improved by 27% to $8.8 million.
- Neutral Sentiment: HC Wainwright reduced its FY2029 EPS estimate to $0.31 from $0.34 but increased its FY2030 forecast to $0.72 from $0.69. The firm’s $14 target and Buy rating were unchanged, suggesting near-term forecast pressure but stronger longer-term expectations.
- Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 plans. Their remaining ownership stakes declined only modestly, reducing the significance of the sales as a bearish signal.
- Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the expected $0.21 loss. The company remains deeply unprofitable, with a negative net margin and analysts forecasting a full-year loss of approximately $0.58 per share.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}